2002

TAG at 10: The Year 1993
TAGline - Volume 9 Issue 2 - March 2002
Jan 8 TAG meets with NIH Director Bernadine Healy re: the NIH Office of AIDS Research (OAR) legislation. She s non-committal. Jan 16 Hoffmann-La Roche community meeting disrupted by ACT UP and TAG. Shrimp cocktail goes flying. Two arrests. Jan 20 Bill Clinton sworn in as 42nd U.S. President. Jan 21 Senator Kennedy


Once We Were Warriors: Activist Corpses Borne In Protest, Furtive Legislative Coups, And The Devastation That Was Berlin
TAGline - Volume 9 Issue 2 - March 2002
We re scientists not alchemists Gregg Gonsalves, Basic Research on HIV Infection: A Report from the Front, 1 June 1993 -------------------- Data are willfully misinterpreted. Time is wasted. Money is wasted. Lobbyists and legislators set research priorities. Hopes are dashed. We are trapped in the outdated clinical re


Mobilizing the Troops: Newly International North American Activist Alliance Gathers in Vancouver 'Gathering strength to fight'
TAGline - Volume 9 Issue 1 - January-February 2002
For the first time ever, NATAF (newly renamed from the National AIDS Treatment Activists Forum to the North American AIDS Treatment Action Forum) took place outside of the U.S., in the beautiful Canadian city of Vancouver, British Columbia. Over 450 delegates from around the U.S. and Canada joined others from Easte


The Importance of Letting T-Cells Take a Rest
TAGline - Volume 9 Issue 1 - January-February 2002
One interesting aspect of Merck s vaccine study appears to have escaped comment. The data comprised two sets of studies, one set evaluating the vaccine vectors given singly while the second set combined the DNA vector with either Ad5 or MVA in a prime-boost regimen. In the former studies, macaques were challenged with


A Tale of Two Trials: Vaccine Researcher Questions the Need for Massive ALVAC Studies
TAGline - Volume 9 Issue 1 - January-February 2002
The week following the publication of the Merck studies, John Moore became the first researcher to speak up about another muffled controversy: the plans for two separate, massive phase III trials of Aventis Pasteur s canarypox-based HIV vaccine (ALVAC). Moore s commentary, also published in Nature, suggests that an exc


Revenge of the CTLs: Harvard Vaccine Team Exposes Potential Dark Side of Reliance on Cellular Immune Protection
TAGline - Volume 9 Issue 1 - January-February 2002
The fate of monkey #798 January 2002 proved to be a month of mixed blessings for the AIDS vaccine field. A slew of new papers in the prestigious journal Nature publicly highlighted both the promise and potential pitfalls of new immunization strategies, raising the volume of scientific debates that have been quietly pre


TAG at 10: The Year 1992
TAGline - Volume 9 Issue 1 - January-February 2002
Jan 22 Treatment Action Group (TAG) splits off from the Treatment + Data (T+D) Committee of ACT UP/New York. Our media debut: Catherine Woodard s AIDS Hit Squad Seeks More Than Attention, Newsday, 1.22.92. Jan 27 Eight Treatment Action Guerillas chain themselves to trucks at the entrance to Astra Pharmaceuticals (now p


Annals of Crisis: A Peek Back At TAG's First Year Shows How Much, And How Little, Has Changed 'Homing in on basic research'
TAGline - Volume 9 Issue 1 - January-February 2002
The beginning of this year marks TAG s tenth anniversary as the nation s only organization focused exclusively on advocating for more and better AIDS research, speeding discovery, development, approval, and distribution of better treatments, a cure and a vaccine. While the latter two goals remain elusive, the past ten



This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 2002. AEGiS.